Arrowhead Pharmaceuticals, Inc. [ARWR] saw a change by -0.91% with the Thursday trading session, closing the trade at the price of $26.13. The company is holding 93.27M shares with keeping 86.49M floating shares. With the latest trading session, the stock is set at 151.01% off compared to its 52-week low, sliding -5.63% from high for the same period of time.
Since its 90-day high, the share price saw a move by -5.63%, trading +51.30% in oppose to its 90-day low While during the day, 93.27M shares valued at 1.77 million were bought and sold.
Arrowhead Pharmaceuticals, Inc. [NASDAQ:ARWR]: Analyst Rating and Earnings
Pro stock market traders often keep their attention pointed at what top market analysts have to say regarding a potential equity investment. For Arrowhead Pharmaceuticals, Inc. [ARWR] currently, the latest-available mean analyst rating is for the fiscal quarter that will end in September. On average, stock market experts give ARWR an Outperform rating. Its stock price has been found in the range of 10.41 to 27.69. This is compared to its latest closing price of $26.37.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Arrowhead Pharmaceuticals, Inc. [ARWR] is sitting at 1.80. This is compared to 1 month ago, when its average rating was 1.80.
For the quarter ending in Mar-19 Arrowhead Pharmaceuticals, Inc. [ARWR] generated $0.05 billion in sales. That’s 12.00% higher than the average estimate of $0.04 billion as provided by Wall Street analysts. The three indicators above suggest that overall, this stock is demonstrating a mixed bag of positive appeal and some drawbacks, making it a somewhat risky investment that also has the potential to generate high ROI in the long run.
Keep your eyes peeled for this company’s upcoming financial results publication, which is slated for Tue 6 Aug (In 53 Days).
Fundamental Analysis of Arrowhead Pharmaceuticals, Inc. [ARWR]
Now let’s turn to look at profitability: with a current Operating Margin for Arrowhead Pharmaceuticals, Inc. [ARWR] sitting at -346.52, this company’s Net Margin is now 10.10%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.
This company’s Return on Total Capital is -61.82, and its Return on Invested Capital has reached -57.00%. Its Return on Equity is -61.45, and its Return on Assets is -50.50. These metrics suggest that this Arrowhead Pharmaceuticals, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
Turning to investigate this organization’s capital structure, Arrowhead Pharmaceuticals, Inc. [ARWR] has generated a Total Debt to Total Equity ratio of 2.43. Similarly, its Total Debt to Total Capital is 2.37, while its Total Debt to Total Assets stands at 2.08. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 2.19, and its Long-Term Debt to Total Capital is 2.14. This company has a healthy balance between its debt and its current holdings, suggesting it is a reliable investment due to its ability to leverage debt in an efficient way.
What about valuation? This company’s Enterprise Value to EBITDA is -48.61. The Enterprise Value to Sales for this firm is now 26.27, and its Total Debt to Enterprise Value stands at 0.00.
Shifting the focus to workforce efficiency, Arrowhead Pharmaceuticals, Inc. [ARWR] earns $139,158 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 81.70 and its Total Asset Turnover is 0.15. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 6.37 and its Current Ratio is 6.37. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Arrowhead Pharmaceuticals, Inc. [ARWR] has 93.27M shares outstanding, amounting to a total market cap of $2.44B. Its stock price has been found in the range of 10.41 to 27.69. At its current price, it has moved down by -5.63% from its 52-week high, and it has moved up 151.01% from its 52-week low.
This stock’s Beta value is currently 1.66, which indicates that it is 3.31% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 66.61. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Arrowhead Pharmaceuticals, Inc. [ARWR] a Reliable Buy?
Shares of Arrowhead Pharmaceuticals, Inc. [ARWR], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.